FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907344722> ?p ?o ?g. }

• W2907344722 endingPage "1075" @default.
• W2907344722 startingPage "1066" @default.
• W2907344722 abstract "Abstract Background Using data from four tertiary referral centers in the U.S., we assessed real-world treatment patterns and clinical outcomes of patients with advanced lung neuroendocrine tumors (NETs). Subjects, Materials, and Methods We performed a retrospective chart review of adult patients with locally advanced/metastatic (typical/atypical) lung NETs treated between July 2011 and December 2014. Index date was histologically confirmed typical/atypical carcinoid tumor diagnosis date. Data included baseline characteristics, treatment patterns, progression, death, and lung NET-related health care resource use from index date through last contact/death. Time to treatment discontinuation and first progression, time from first to second progression, and overall survival (OS) were estimated using Kaplan-Meier analysis. Results We identified 83 patients; 19 (23%) had functional NET. First-line treatments included somatostatin analogs (SSAs) alone (56%) or in combination with other therapies (6%), cytotoxic chemotherapy (20%), external beam radiation therapy (EBRT) (9%), liver-directed therapy (LDT) (4%), and everolimus/other (5%). Sixty patients had second-line therapy including SSA alone (18%) or in combination (40%), cytotoxic chemotherapy (17%), everolimus (12%), LDT (7%), EBRT (3%), and other treatments (3%). Median time (months) to first-line discontinuation were as follows: SSAs, 43.3; cytotoxic chemotherapy, 3.6. Overall median time (months) to investigator-assessed progression following treatment initiation was 12.4. Median OS (months) following treatment initiation was 66.4 for all patients and 81.5 for patients receiving SSAs. Conclusion SSAs, alone and in combination, are common treatments for advanced lung NETs. Patients have additional treatment options and relatively long survival compared with patients with other advanced cancers. Treatment pattern assessment following approval of newer treatments is needed." @default.
• W2907344722 created "2019-01-11" @default.
• W2907344722 creator A5001118053 @default.
• W2907344722 creator A5016574266 @default.
• W2907344722 creator A5017947396 @default.
• W2907344722 creator A5018549978 @default.
• W2907344722 creator A5026542617 @default.
• W2907344722 creator A5029706633 @default.
• W2907344722 creator A5033960518 @default.
• W2907344722 creator A5038383749 @default.
• W2907344722 creator A5047448453 @default.
• W2907344722 creator A5055590642 @default.
• W2907344722 creator A5056390133 @default.
• W2907344722 creator A5063896009 @default.
• W2907344722 creator A5072727753 @default.
• W2907344722 creator A5089106286 @default.
• W2907344722 date "2019-01-04" @default.
• W2907344722 modified "2023-10-14" @default.
• W2907344722 title "Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study" @default.
• W2907344722 cites W2011916383 @default.
• W2907344722 cites W2054560648 @default.
• W2907344722 cites W2149214723 @default.
• W2907344722 cites W2154183223 @default.
• W2907344722 cites W2274265211 @default.
• W2907344722 cites W2489424206 @default.
• W2907344722 cites W2556634813 @default.
• W2907344722 cites W2567822129 @default.
• W2907344722 cites W2587129213 @default.
• W2907344722 cites W2593718348 @default.
• W2907344722 cites W2608160487 @default.
• W2907344722 cites W2789522327 @default.
• W2907344722 cites W3192494717 @default.
• W2907344722 doi "https://doi.org/10.1634/theoncologist.2018-0520" @default.
• W2907344722 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6693720" @default.
• W2907344722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30610008" @default.
• W2907344722 hasPublicationYear "2019" @default.
• W2907344722 type Work @default.
• W2907344722 sameAs 2907344722 @default.
• W2907344722 citedByCount "9" @default.
• W2907344722 countsByYear W29073447222020 @default.
• W2907344722 countsByYear W29073447222021 @default.
• W2907344722 countsByYear W29073447222023 @default.
• W2907344722 crossrefType "journal-article" @default.
• W2907344722 hasAuthorship W2907344722A5001118053 @default.
• W2907344722 hasAuthorship W2907344722A5016574266 @default.
• W2907344722 hasAuthorship W2907344722A5017947396 @default.
• W2907344722 hasAuthorship W2907344722A5018549978 @default.
• W2907344722 hasAuthorship W2907344722A5026542617 @default.
• W2907344722 hasAuthorship W2907344722A5029706633 @default.
• W2907344722 hasAuthorship W2907344722A5033960518 @default.
• W2907344722 hasAuthorship W2907344722A5038383749 @default.
• W2907344722 hasAuthorship W2907344722A5047448453 @default.
• W2907344722 hasAuthorship W2907344722A5055590642 @default.
• W2907344722 hasAuthorship W2907344722A5056390133 @default.
• W2907344722 hasAuthorship W2907344722A5063896009 @default.
• W2907344722 hasAuthorship W2907344722A5072727753 @default.
• W2907344722 hasAuthorship W2907344722A5089106286 @default.
• W2907344722 hasBestOaLocation W29073447221 @default.
• W2907344722 hasConcept C126322002 @default.
• W2907344722 hasConcept C141071460 @default.
• W2907344722 hasConcept C143998085 @default.
• W2907344722 hasConcept C167135981 @default.
• W2907344722 hasConcept C2776256026 @default.
• W2907344722 hasConcept C2776694085 @default.
• W2907344722 hasConcept C2778715236 @default.
• W2907344722 hasConcept C2779066768 @default.
• W2907344722 hasConcept C2779699572 @default.
• W2907344722 hasConcept C71924100 @default.
• W2907344722 hasConceptScore W2907344722C126322002 @default.
• W2907344722 hasConceptScore W2907344722C141071460 @default.
• W2907344722 hasConceptScore W2907344722C143998085 @default.
• W2907344722 hasConceptScore W2907344722C167135981 @default.
• W2907344722 hasConceptScore W2907344722C2776256026 @default.
• W2907344722 hasConceptScore W2907344722C2776694085 @default.
• W2907344722 hasConceptScore W2907344722C2778715236 @default.
• W2907344722 hasConceptScore W2907344722C2779066768 @default.
• W2907344722 hasConceptScore W2907344722C2779699572 @default.
• W2907344722 hasConceptScore W2907344722C71924100 @default.
• W2907344722 hasIssue "8" @default.
• W2907344722 hasLocation W29073447221 @default.
• W2907344722 hasLocation W29073447222 @default.
• W2907344722 hasLocation W29073447223 @default.
• W2907344722 hasLocation W29073447224 @default.
• W2907344722 hasLocation W29073447225 @default.
• W2907344722 hasOpenAccess W2907344722 @default.
• W2907344722 hasPrimaryLocation W29073447221 @default.
• W2907344722 hasRelatedWork W1912172143 @default.
• W2907344722 hasRelatedWork W1998085187 @default.
• W2907344722 hasRelatedWork W2043171019 @default.
• W2907344722 hasRelatedWork W2058233712 @default.
• W2907344722 hasRelatedWork W2284646457 @default.
• W2907344722 hasRelatedWork W2719368655 @default.
• W2907344722 hasRelatedWork W2743879516 @default.
• W2907344722 hasRelatedWork W2892920396 @default.
• W2907344722 hasRelatedWork W4362545043 @default.
• W2907344722 hasRelatedWork W4362567748 @default.
• W2907344722 hasVolume "24" @default.
• W2907344722 isParatext "false" @default.

• next